VIDEOS AND WEBINARS

• Ajinomoto Bio-Pharma Services Capacity Update October 2022: Small Molecule

  October 2022 Outsourced Pharma Capacity Update presenter Ajinomoto Bio-Pharma Services has been actively producing high quality APIs and intermediates for the pharmaceutical industry for more than 40 years. In this video, learn about their capabilities and available capacity as well as how their experienced and knowledgeable chemists and engineers provide customers the ability to rapidly scale from pilot to commercial product.

• Ajinomoto Bio-Pharma Services Capacity Update October 2022: Large Molecule

  Ajinomoto Bio-Pharma Services highlights the new high speed multi-purpose fill finish line in its state-of-the-art commercial manufacturing facility located in San Diego, CA. They discuss their capabilities and capacity in clinical and commercial manufacturing, including automated visual inspection/semi-automated visual inspection.

• Ajinomoto Bio-Pharma Services' Capabilities And Capacity Update March 2022: Biologics

  Ajinomoto Bio-Pharma Services is a leading provider of biopharmaceutical contract development and manufacturing services. The company has expanded current capacity as well as component flexibility with the addition of a high speed multi-purpose fill finish line in its state-of-the-art commercial manufacturing facility located in San Diego, CA. In this presentation, Aji Bio-Pharma will discuss this expanded flexible aseptic fill finish capacity.

• Ajinomoto Bio-Pharma Services' Capabilities and Capacity Update March 2022: Cell & Gene

  Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization providing comprehensive development, cGMP manufacturing, and aseptic fill finish services for small and large molecule APIs and intermediates. In this presentation, Aji Bio-Pharma will discuss the capacity, expertise, and equipment available for drug substance and plasmid manufacturing for gene therapies.

• Providing Value Optimized, Time Saving Oligo Solutions

  Whether you are in the beginning research stages or ready to take your product to market, our scalable, high quality, and custom oligo and peptide solutions provide the quantities you need using the most reliable, robust, and cost-effective process available.

• Rising To Meet Increasing Demand For Microbial Based Biologics

  The production of your biotherapeutic deserves the reliability and peace of mind that only a trusted and experienced microbial fermentation partner can provide. Ajinomoto Bio-Pharma Services is a recognized leader in recombinant protein, plasmid DNA, and critical raw material manufacturing for vaccine and gene therapy applications.

• Custom Pharmaceutical Packaging, Labeling And Shipping Services

  Consolidate your supply chain by having your packaging integrated with your product manufacturing.

• Aseptic Vial Filling

  We offer a unique range of formulation and aseptic filling in vials, prefilled syringes or cartridges to address production needs that span from small early stage clinical products to larger scale commercial products.

• High Potency Fill Line

  Whether it's a liquid or lyophilized product, we provide capacity, quality, and expertise to ensure a stable supply of your promising therapeutics.

• Aji Bio-Pharma and Catalisti

  The HANU, a new photo-flow reactor, provides better process control, less risk in hazardous chemistry, less solvent use, and is better for the environment.

• New High Speed Multi-Purpose Fill Line

  Our fully contained and integrated OPTIMA line utilizes scan isolated barrier technology to ensure the required sterility for fill finish while offering flexibility to meet your cGMP, clinical, and commercial drug product manufacturing needs.

• OPTIMA 7000 Fill Line

  Ajinomoto Bio-Pharma Services is a leader in aseptic filling, offering a wide range of capabilities for vials with our OPTIMA 7000 fill line. The OPTIMA VFVM 7000 safely processes various types and classes of biopharmaceutical products in 2 mL to 100 mL sizes.

• A Fill Finish Manufacturing Partner With Resources, Solutions, And Agility

  We offer a unique range of formulation and aseptic filling in vials, prefilled syringes, or cartridges to address production needs that span from small early stage clinical products to larger scale commercial products.

• Fully Integrated CDMO Services To Improve The Health Of Humankind

  We provide therapeutic drug development and manufacturing services to biotechnology and pharmaceutical companies worldwide. We have the power to make your therapeutic vision a reality — from pre-clinical through commercial production.

• Oligonucleotide Therapeutics: Bridging From Research To Commercial

  Examine the development and manufacturing expertise required to seamlessly transition from research to commercial stages to ensure smooth operation from early to late stage development.

• Considerations For Complex Formulations: How To Simplify Your Outsourcing

  Experts share the necessary development and manufacturing considerations for a smooth tech transfer, exploring these challenges in depth, and discuss the questions you should be asking your manufacturer.

• Plasmid Manufacturing For Gene Therapies: An Outsourcing Partnership

  With an increased demand for plasmids for targeted gene therapeutic delivery, partnering with a CDMO equipped with the capacity, expertise and equipment for plasmid DNA production is critical.

• Sustainable Approaches To Oligonucleotide Manufacturing

  An industry expert shares about sustainable Oligo manufacturing approaches that can save time, cost, and resources – while improving purity, quality, and scalability of these promising therapeutics.

• Are You Protecting Employees During HPAPI Manufacturing?

  Tom Evans, MS, CMMS discusses the planning, resources, and capabilities necessary to effectively produce a client’s highly potent active pharmaceutical ingredient (HPAPI) therapeutic.

• The Paradigm Shift To Continuous Flow Processes: A Holistic View

  A clear increase in continuous flow processes has emerged over the past decade, thanks to the commercialization of preparative flow reactor units.